Brief: Immixbio Approves 4 Additional Clinical Trial Sites For Imx-110 Clinical Trials
18/10/2022 13:18
Oct 18 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIXBIO APPROVES 4 ADDITIONAL CLINICAL TRIAL SITES FOR
IMX-110
CLINICAL TRIALS, COMPLEMENTING EXISTING SOFT TISSUE SARCOMA LEAD
SITE
* IMMIX BIOPHARMA INC - CLINICAL TRIAL DATA EXPECTED TO BE
RELEASED ON A ROLLING BASIS BEGINNING IN Q1 2023
* IMMIX BIOPHARMA INC - CALIFORNIA SOFT TISSUE SARCOMA SITE
TO
LEAD EXPANDED CLINICAL SITE CONSORTIUM
Source text for Eikon: ID:nGNX4K74Xj
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary